Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Placebo-Controlled, Double-Blind, Parallel Group, Fixed Dose Study of KW-6002 (Istradefylline) in the Treatment of Parkinson's Disease (Phase 3)

NCT00955526 is registered in ClinicalTrials.gov with Kyowa Kirin Co., Ltd. as lead sponsor.

NCT NCT00955526
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00955526 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Placebo-Controlled, Double-Blind, Parallel Group, Fixed Dose Study of KW-6002 (Istradefylline) in the Treatment of Parkinson's Disease (Phase 3)
Lead sponsor
Kyowa Kirin Co., Ltd.
Phase
Phase 3
Overall status
Completed
Start date
July 31, 2009
Completion date
February 28, 2011
Enrollment
373 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

parkinson's disease